17

submission to the current journal; gave final approval for the current version to be published; and agree to be accountable for all aspects of the work.\Disclosure Mohammed A. Omair has received speaker’s fees/grants from Abbvie, Actelion, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Hekma, Janssen, New Bridge, Novartis, Pfizer, and Roche. Alper Erdogan is an employee and shareholder of Eli Lilly and Company, Riyadh, Saudi Arabia. Nicole Tietz is an employee and shareholder of Eli Lilly and Company, Indianapolis, IN, USA. Rieke Alten has received research grants and consultancy fees from Abbvie, BMS, Eli Lilly and Company, Gilead, Galapagos, Janssen, Pfizer and UCB. The authors report no other conflicts of interest in this work.\ References\ 1. World Health Organization [internet]. Chronic rheumatic conditions; 2020. Available from: https://www.who.int/chp/topics/rheumatic/en/. Accessed May 19, 2020. 2. Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004–2014. Rheumatol Int. 2017;37(9):1551–1557. doi:10.1007/s00296-017-3726-1 3. Al-Dalaan A, Al Ballaa S, Bahabri S, et al. The prevalence of rheumatoid arthritis in the Qassim region of Saudi Arabia. Ann Saudi Med. 1998;18(5):396–397. doi:10.5144/0256-4947.1998.3964. Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463–1471. doi:10.1136/annrheumdis-2019-215920